Senthilkumar Damodaran
ECOG-ACRIN Cancer Research Group · M.D. Anderson Cancer Center · University of Texas MD Anderson Cancer Center LAO
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Senthilkumar Damodaran as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 17:09 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT05490771 · Testing Copanlisib as a Potential Targeted Treatment in Cancers With PIK3CA Mutations (MATCH-Subprotocol Z1F)National Cancer Institute (NCI) · active not recruiting · Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphatic System Neoplasm · principal investigator
- Ph2NCT04256941 · Aromatase Inhibitor Therapy With or Without Fulvestrant for the Treatment of HR Positive Metastatic Breast Cancer With an ERS1 Activating Mutation, the INTERACT StudyM.D. Anderson Cancer Center · terminated · Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8 · principal investigator
- Ph2NCT04216472 · Nab-paclitaxel and Alpelisib for the Treatment of Anthracycline Refractory Triple Negative Breast Cancer With PIK3CA or PTEN AlterationsM.D. Anderson Cancer Center · terminated · Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8 · principal investigator
- Ph1/Ph2NCT04108858 · Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Maintenance Treatment (Trastuzumab and Pertuzumab) After Initial Chemotherapy in a Phase Ib/II Trial for Advanced HER2 Positive Breast CancerNational Cancer Institute (NCI) · terminated · Anatomic Stage IV Breast Cancer AJCC v8, HER2-Positive Breast Carcinoma, Metastatic Breast Carcinoma · principal investigator
- Ph1NCT03579472 · M7824 and Eribulin Mesylate in Treating Patients With Metastatic Triple Negative Breast CancerM.D. Anderson Cancer Center · terminated · Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8 · principal investigator
- Ph2NCT01334021 · Genetic Testing in Predicting Tumor Response in Patients With Stage I-III HER2 Negative Invasive Breast CancerM.D. Anderson Cancer Center · active not recruiting · Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8 · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 17:09 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- University of Texas PDX Development and Trial CenterU54CA224065 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2022 · $199,970 awarded in 2022Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- ECOG-ACRIN Network Group Operations CenterU10CA180820 · NCI · ECOG-ACRIN MEDICAL RESEARCH FOUNDATION · PI Peter J ODwyer, MITCHELL D. SCHNALL · fiscal years 2016 to 2026Named on NCT05490771
- ECOG-ACRIN Biospecimen Bank to Support NCTNU24CA196172 · NCI · ECOG-ACRIN MEDICAL RESEARCH FOUNDATION · PI STANLEY R. HAMILTON, Scott D Jewell · fiscal years 2017 to 2026Named on NCT05490771
- Texas EXperimental Cancer Therapeutics Network - TEX CTNUM1CA186688 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI FUNDA MERIC-BERNSTAM, John Sarantopoulos, James C Yao · fiscal years 2016 to 2026Named on NCT04108858
- Experimental Medicine ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI FUNDA MERIC-BERNSTAM · fiscal years 2016 to 2026Named on NCT03579472
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 17:09 UTC. The ranking covers the 200 most relevant of 19 PubMed records, and a shared surname and initials can bring in a namesake. All 19 on PubMed
- Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2- and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study.J Clin Oncol · 2024176 citationsRCR 21.9
- Neoadjuvant Talazoparib for Patients With Operable Breast Cancer With a Germline BRCA Pathogenic Variant.J Clin Oncol · 2020173 citationsRCR 6.9
- Phase II Study of Copanlisib in Patients With Tumors With PIK3CA Mutations: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1F.J Clin Oncol · 202271 citationsRCR 4.4
- Immune Phenotype and Response to Neoadjuvant Therapy in Triple-Negative Breast Cancer.Clin Cancer Res · 202169 citationsRCR 3.2
- Quetiapine v. lithium in the maintenance phase following a first episode of mania: randomised controlled trial.Br J Psychiatry · 201752 citationsRCR 2.6
- 46 citationsRCR 3.2
- 44 citationsRCR 3.1
- Molecular Characterization and Prospective Evaluation of Pathologic Response and Outcomes with Neoadjuvant Therapy in Metaplastic Triple-Negative Breast Cancer.Clin Cancer Res · 202240 citationsRCR 2.6
- Phase II study of Radium-223 dichloride combined with hormonal therapy for hormone receptor-positive, bone-dominant metastatic breast cancer.Cancer Med · 202023 citationsRCR 1.3
- A phase II study of Mirvetuximab Soravtansine in triple-negative breast cancer.Invest New Drugs · 202122 citationsRCR 1.1